PURA - Puration Pursues $9 Billion Market With Latin American Acquisition Scheduled To Close Next Week
November 27 2019 - 10:46AM
InvestorsHub NewsWire
PURA – Puration Pursues $9 Billion
Market With Latin American Acquisition Scheduled To Close Next
Week
Dallas, TX -- November 27, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced the company has scheduled to close the
purchase of a Latin American company intended enable PURA to bottle
CBD beverages in Latin America for the Latin American market.
The closing is scheduled for next week, on Thursday, December 5,
2019. The legal Latin American cannabis market is anticipated
to reach $9 billion by
2028.
PURA recently closed an acquisition to
enable PURA to bottle CBD Beverages in Europe for the European
market. The acquisition initiative in Europe was driven by
PURA recently signing a distribution
agreement in
Europe for its EVERx CBD
Sports Water with other CBD infused beverages to
follow. The initial European distribution agreement is
estimated to add $4 million in sales next year. Management
indicates that the potential of European distribution beyond the
initial $4 million projection warrants the establishment of a local
bottling capacity. The European market for CBD is projected
to reach nearly US $17 billion
by 2023. The bottling expansion in Europe
is part of a bigger plan to expand bottling in Canada and Latin
America.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024